Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Giotrif

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    Lilly announces plan for new $3bn facility to boost manufacturing in Europe

    The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    EU medicine shortages hit record highs in 2023 and 2024

    Even with countermeasures in place, European auditors warn that the risks remain elevated

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    ECA webinar image

    ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

    On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...

    Genesis Research Group

    - PMLiVE

    Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

    Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links